Another study by Tikum et al., in preclinical models carrying colorectal and breast cancer, used [89Zr]Zr-DFO-matuzumab, targeting a different EGFR epitope compared to nimotuzumab, and showed high specificity for EGFR. Here, EGFR is linked to breast carcinoma.